Silver Book Fact

Direct thrombin inhibitor reduced relative risk of venous thromboembolism

An investigational direct thrombin inhibitor reduced relative risk of venous thromboembolism after total hip replacement surgery by 65.7%—compared to a currently available treatment.

Fuji T, Fujita S, Kawai Y, Nakamura M, et al. Efficacy and Safety of Edoxaban Verus Enoxaparin for the Prevention of Venous Thrombembolism Following Total Hip Arthroplasty: STARS J-V Trial. Orlando, Florida: American Society of Hematology,2010 Annual Meeting; 2015. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534125/pdf/12959_2015_Article_57.pdf

Reference

Title
Efficacy and Safety of Edoxaban Verus Enoxaparin for the Prevention of Venous Thrombembolism Following Total Hip Arthroplasty: STARS J-V Trial
Publisher
American Society of Hematology,2010 Annual Meeting
Publication Date
2015
Authors
Fuji T, Fujita S, Kawai Y, Nakamura M, et al.
Volume & Issue
Volume 13, Issue 27
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Medicines in Development for Heart Disease and Stroke, 2008  
  • According to the National Center for Health Statistics, if all major forms of cardiovascular disease were eliminated, life expectancy would rise by close to 7 years.  
  • Identifying individuals at high risk for developing AFib
    Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.  
  • 277 medicines are currently in development to treat or prevent heart disease and stroke.  
  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…